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ABST RACT
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome
is a potentially life-threatening, idiosyncratic, acute adverse drug reaction.
Fever, morbilliform cutaneous eruption, and eosinophilia are essential
features for the diagnosis of this syndrome, along with significant
multisystem involvement, hepatitis being the most common, followed by
nephritis. The pathogenesis of DRESS syndrome is not yet fully understood.
Several hypotheses have been proposed which support the involvement of
an intricate interplay of multiple factors. We report a clinical case of DRESS
syndrome with renal injury, induced by carbamazepine, in a patient with
alcohol abstinence syndrome. In order to define the case, the RegiSCAR
score and the Japanese Group score, used in the diagnosis of drug-induced
hypersensitivity, were applied. DRESS syndrome is a potentially fatal
disease, with a mortality that can reach up to 40% of cases. This condition
endangers the patient's life by affecting the internal organs, mainly the liver,
kidneys, heart, and lungs. Our case attempts to increase awareness among
physicians about this serious disease and the importance of early diagnosis,
especially since carbamazepine is a commonly used anticonvulsant drug.

Introduction
Drug reaction with eosinophilia and systemic
symptoms (DRESS) syndrome is a potentially lifethreatening, idiosyncratic, acute adverse drug reaction [1].
The incidence of this syndrome is estimated to range from
1:1000 to 1:10000 of drug exposures [2]. The overall
mortality rate of this disease is 10-20% [3], but there are
studies that present higher mortality rates, up to 40% if
organ failure is present [4]. Fever, morbilliform cutaneous
eruption, and eosinophilia are essential features for the
diagnosis of this syndrome, along with significant
multisystem involvement, hepatitis being the most
common, followed by nephritis [3]. Highly suggestive of
this condition is latency between initial drug administration
and specific symptom onset [5]. The pathogenesis of
DRESS syndrome is not yet fully understood. Several
hypotheses have been proposed which support the
involvement of an intricate interplay of multiple factors
such as: mutations in genes encoding drug detoxification
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enzymes leading to the accumulation of drug reactive
metabolites, reactivation of human herpes virus 6 and 7,
Epstein-Barr virus (EBV), cytomegalovirus (CMV),
genetic predisposition associated with certain human
leukocyte antigens (HLA), and immunological phenomena
[6]. Common drugs associated with DRESS syndrome are
anticonvulsants (such as carbamazepine, phenytoin) [7].
The first step in treating the disease is prompt recognition
and early discontinuation of the drug involved [8].
Systemic
glucocorticoid
therapy,
intravenous
immunoglobulin, antiviral drugs, plasmapheresis,
cyclosporine, and symptomatic treatment are part of the
appropriate management of this pathology [3]. In DRESS
syndrome patients, careful long-term follow-up is crucial
and monitoring for autoimmune diseases is required [5].

Case Presentation
A 46-year-old man was admitted to the Department of
Internal Medicine with a history of high fever (40.1°C),
diffuse pruritic morbilliform cutaneous eruption which had
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been continuing over the last ten days. Two days before
hospitalization, the patient's condition worsened, with
edema affecting his face and hands. Approximately 6
weeks before, treatment with carbamazepine and vitamin
B supplements for his alcohol abstinence syndrome was
initiated. The patient’s medical history was notable for
alcohol abuse, alcoholic steatosis, mitral valve
regurgitation, and pulmonary tuberculosis. It is also
important to mention that, prior to hospitalization, the
patient underwent antibiotic treatment with ampicillin.
On physical examination, his consciousness was clear
and his general status was moderate, with a body
temperature of 39.3°C, a heart rate of 100 beats per minute,
a blood pressure of 100/70 mmHg, and an oxygen
saturation of 99%. The patient had important edema of his
face and hands, and a diffuse maculopapular erythematous
eruption. He also had purpuric lesions on the lower
extremities. There was no conjunctival involvement. At the
time of admission, no palpable lymph nodes were
identified. Apart from tachycardia, cardiovascular
examination was normal. The respiratory system was clear
bilaterally, without rhonchi or crackles. Digestive system
examination revealed the presence of hepatomegaly. There
were no signs of focal neurological deficits.
On the day of the admission to our hospital, the patient
was referred to an infectious disease specialist, who
diagnosed him with acute pharyngitis, interstitial
pneumonia, and polymorphous erythema, and prescribed
treatment with antibiotics (macrolides: Azithromycin 500
mg/day for 5 days or Clarithromycin 2x500 mg/day for 7
days), antihistamines, and antipyretic drugs. He also
recommended a chest X-ray and serological tests for
Chlamydia, Mycoplasma, hepatitis B and C, HIV, and
syphilis.
Laboratory findings at the time of admission revealed
neutrophilia and lymphopenia, a low red blood cell count,
a low hematocrit, macrocytosis, and a normal erythrocyte
sedimentation rate. The coagulation workup showed a
prolonged prothrombin time. The patient’s biochemical
tests evidenced an aspartate aminotransferase (ALT) level
slightly above the upper limit, increased gamma-glutamyl
transferase, a low plasma iron level, hypoproteinemia, and
elevated C-reactive protein. Urinalysis showed a low urine
density and the presence of urobilinogen in the sample.
Blood samples for hemocultures were also collected and
came back negative.
Abdominal sonography showed hepatomegaly. Chest
radiography revealed a 2/2 cm cavity in the right lung,
suggestive of an old TB lesion, and also raised the
suspicion of interstitial pneumonia. Electrocardiography
evidenced sinus tachycardia. The transthoracic
echocardiogram results raised the suspicion of mitral valve
vegetation, so we referred the patient for a transesophageal
echocardiogram. The echocardiogram also revealed
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pulmonary valve, mitral valve, and tricuspid valve
regurgitations. Neck ultrasound showed the presence of
round and hypoechoic lymphadenopathy.
The suspicion of DRESS syndrome caused by
carbamazepine was raised based on clinical examination,
laboratory tests, and imaging investigations, and the patient
was referred to a dermatologist. During physical
examination, besides the rash, the doctor also identified
enlarged lymph nodes in the inguinal area. The
dermatologist confirmed our suspicion of DRESS
syndrome and recommended treatment with prednisone 1
mg/kg, emollient cream, and a number of laboratory tests
including hepatitis C antibodies, HBs antigen, and also
tests for Epstein-Barr virus, cytomegalovirus, and herpes
simplex virus. The doctor also recommended cessation of
carbamazepine administration and monitoring of renal
function and blood cell count.
Carbamazepine was immediately withdrawn and no
other anticonvulsants were administered. Treatment with
peroral prednisone 1 mg/kg and symptomatic medication
was administered. We also monitored our patient’s blood
cell count, renal function, blood pressure, heart rate, body
temperature, and oxygen saturation.
During the following weeks, the patient’s
maculopapular exanthema progressed towards exfoliative
erythroderma, with marked exfoliative facial dermatitis
(Figure 1).

Figure 1. Exfoliative facial dermatitis: marked
erythema and fissures of the facial skin
The laboratory tests improved until the third week of
hospitalization, when new complete blood count
alterations with leukocytosis (14.02x109 /L) and extensive
eosinophilia (3.93x109 /L) were found. The biochemical
tests revealed low total proteins and the urine tests showed
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proteinuria. It was also observed that CK-MB levels were
slightly above the upper limit. Taking into consideration
the high eosinophil count, we performed a parasitological
stool examination, which detected no parasite eggs or
cysts. The eosinophil levels remained high for
approximately one week. We continued the treatment
recommended by the dermatologist, and the patient’s
health and laboratory tests improved.
After 4 weeks of hospitalization, our patient was
released with no symptoms and improved laboratory tests,
and we prescribed prednisone 25 mg/day (with gradually
decreasing doses by 5 mg per week), and emollients for his
face, thorax and hands. We also recommended avoiding
anticonvulsants such as carbamazepine, phenytoin,
phenobarbital, or other medications associated with
DRESS syndrome.

Discussions
DRESS syndrome is a severe, potentially fatal,
idiosyncratic adverse drug reaction [1]. Classical diagnosis
is based on skin lesions, fever, and eosinophilia. Rash is the
most common feature of this disease and is present in 73100% of patients. The pattern of the lesions varies from one
patient to another. Typically, they involve more than 50%
of the body surface and have a polymorphic presentation
such as infiltrative papules, plaques which resemble
urticarial, target-like or eczema-like lesions [7, 8]. Facial
edema is present in 76% of cases. Regarding organ
damage, the liver (75%), kidneys (37%), and lungs (32%)
are frequently affected [9]. There are atypical presentations
of DRESS syndrome with cardiac, neurologic,

gastrointestinal, and endocrine manifestations [1]. Our
patient presented all the classic clinical features of this
syndrome, with important facial edema that disfigured his
physiognomy. In addition, the patient had mucosal
involvement with pharyngeal erythema. Mucosal
membranes are often affected by this disease [5].
Enlarged lymph nodes are also present in 54% of the
patients. They can be a clinical finding or revealed by
imaging [7]. In our patient, lymph node involvement was
identified both by physical examination and neck
ultrasonography.
Risk factors for renal involvement in DRESS syndrome
include old age and a medical history of kidney disease or
cardiovascular diseases [7]. In our patient, the kidney
injury manifested as proteinuria, but his renal function
recovered completely. Kidney involvement is most
commonly seen in DRESS syndrome caused by
administration of allopurinol, followed by carbamazepine
[1].
Pulmonary involvement in DRESS syndrome is not
only defined by clinical findings (cough, dyspnea), but also
by chest X-ray. The most common imaging sign of lung
injury is interstitial pneumonitis [10]. Our patient’s chest
radiography raised the suspicion of interstitial lung injury,
but without any clinical signs of respiratory symptoms.
Eosinophilia was absent in the first 3 weeks of
hospitalization and registered high values only on the 23rd
day after admission. It is well known that eosinophilia is
often absent initially in DRESS syndrome [5]. The white
blood cell count tests in the reported patient are presented
in Table I.

Table I. White blood cell count tests in the reported patient
Laboratory parameter

Day 1

Day 2

Day 4

Day 8

Day 23

Day 28

WBC (10∧3/ul)

5.21

6.75

9.40

16.51

14.02

14.36

EO%

0.0

0.0

1.1

0.4

28.0

18.7

EO# (10∧3/ul)

0.00

0.00

0.10

-

3.93

2.69

WBC white blood cell count, EO eosinophils
In our case, the culprit drug was carbamazepine.
Aromatic anticonvulsants (phenytoin, carbamazepine,
phenobarbital) are metabolized by cytochrome P450 with
the formation of toxic reactive metabolites, which under
physiological conditions are converted by epoxide
hydroxylase or glutathione transferase to non-toxic
components. If these pathways are deficient, the
accumulation of toxic metabolites results in altered
immune responses and cellular damage [11]. Ampicillin,
another drug known to cause DRESS syndrome, was
administered to the patient [7]. The relationship between
the antibiotic and the pathogenesis of this idiosyncratic

reaction was excluded by the short time interval between
drug administration and symptom onset.
For the diagnosis of DRESS syndrome, we applied the
RegiSCAR criteria for hospitalized patients and the
Japanese Group score, used in the diagnosis of druginduced hypersensitivity. Thus, the case was categorized as
definite DRESS syndrome with a score of 7, atypical
DRESS syndrome, respectively [12]. The RegiSCAR
scoring and the Japanese Group scoring for diagnosis of
DRESS syndrome and our case estimations are presented
in Table II and Table III.
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Table II. RegiSCAR scoring system for diagnosis of DRESS syndrome and our case estimation [12].
CRITERIA

SCORE
NO

YES

UNKNOWN

CASE SCORE

Fever ≥38.5°c

-1

0

-1

0

Enlarged lymph nodes ≥2 sites and >1cm

0

1

0

1

Peripheral eosinophilia
• 0.7-1.5x109/l or 10-19.9%
• ≥1.5x109/l or ≥20%

0

1
2

0

Atypical lymphocytes

0

1

0

0

Skin involvement
• Extent of cutaneous eruption ≥50%
• Skin rash suggesting DRESS
• Biopsy suggesting DRESS

0
-1
-1

1
1
0

0
0
0

1
1
0

0

1
2

-1

0

-1

0

0

1

0

1

Organ involvement
• One
• 2 or more
Resolution ≥15 days
Laboratory results negative for at least 3 of the
following
• ANA, blood culture, HAV/HBV/HCV
serology, Chlamydia/Mycoplasma serology

2

1
0

7

Total score <2 no case; 2-3 possible case; 4-5 probable case; >5 definite

Table III. Japanese Group scoring system for diagnosis of DRESS syndrome and our case estimation [12].
CRITERIA

CASE SCORE

Maculopapular rash developing >3 weeks after drug initiation

1

Clinical symptoms continuing >2 weeks after stopping therapy

1

Fever >38°C

1

Liver abnormalities (ALT>100 IU/L) or other organ involvement

1

Hematological abnormalities
• Leukocytosis
• Atypical lymphocytes
• Eosinophilia

1

Lymphadenopathy

1

Human herpes 6 reactivation

0

7=typical DRESS syndrome; 5=atypical DRESS syndrome;
<5 consider other diagnosis

6

ALT Alanine transaminase

242

Carbamazepine-induced DRESS syndrome

The diagnosis of DRESS syndrome requires a high
level of suspicion, and differential diagnosis includes a
large number of maladies such as infectious diseases
(especially viral exanthema, particularly EBV infectious
mononucleosis) [7], graft versus host disease [13],
autoimmune diseases (Still’s disease, Kawasaki disease),
and neoplastic diseases [14]. The presence of neoplasia,
infections, or collagenosis in our patient was excluded
following imaging investigations and clinical
consultations [3].
The appropriate treatment of DRESS syndrome is
mainly supportive and symptomatic. The first step in the
management of this disease is prompt withdrawal of the
culprit drug. In case of organ involvement, the use of
systemic corticosteroids (1 mg/kg/day) is recommended. If
there is renal or lung injury, systemic glucocorticoid
therapy is necessary until the clinical signs and the
laboratory investigations normalize. Sometimes, pulsed
methylprednisolone therapy is required [3]. If organ
involvement is severe and life-threatening, intravenous
immunoglobulin therapy should be associated with
systemic corticosteroids [5]. In resistant cases,
plasmapheresis could be a therapeutic option [15]. If
corticotherapy is not efficient, cyclosporine can be used as
a second line option in DRESS syndrome cases with severe
organ involvement [3]. When virus reactivation is
demonstrated, ganciclovir may be given in addition to
intravenous globulin and systemic corticosteroids, but the
efficiency of antiviral drugs in DRESS syndrome is not
well documented [5]. In patients with exfoliative
dermatitis, maintaining the skin barrier and proper
hydration are essential to adequate management.
Symptomatic treatment consists of emollients, topical
corticosteroids, and antihistamines. After DRESS
syndrome diagnosis, in our case, the first therapeutic step
was to stop the administration of carbamazepine. The
treatment we gave to our patient consisted of oral
corticosteroids (prednisone 1 mg/kg), intravenous fluids,
and symptomatic medication (H1-antihistamines for relief
of pruritus).
Recovery of DRESS syndrome patients occurs
gradually and takes weeks or even months [3]. Our patient
fully recovered after 4 weeks of hospitalization. The
evolution of these patients is marked by flare-ups even
after using structurally different drugs. In case of
reoccurrence, the most frequent findings are skin rashes
and cell blood count abnormalities with eosinophilia [7].
The long-term sequelae of DRESS syndrome include
autoimmune phenomena (autoimmune thyroid disease,
type 1 diabetes mellitus, systemic sclerosis, and systemic
lupus erythematosus) [16]. Taking into consideration the
morbidity of these patients, careful follow-up is essential
in order to identify recurrences or the development of
autoimmune diseases. In our patient’s case, during follow-

up until now, there have been no recurrences of DRESS
syndrome or manifestations of autoimmunity.

Conclusions
In patients with DRESS syndrome, early diagnosis and
prompt intervention may improve outcomes. The diagnosis
of this syndrome is often delayed due to polymorphic
manifestations and to the long time period between
administration of the culprit drug and symptom onset.
Physicians should always keep in mind that the basic step
in the disease management is immediate discontinuation of
the suspected drug. Our case represents a DRESS
syndrome induced by carbamazepine, an aromatic
anticonvulsant. Our patient exhibited common signs and
symptoms: morbilliform rash, fever, and eosinophilia.
Apart from cutaneous manifestations, organ involvement
was present with renal and pulmonary injury. Our case
attempts to increase awareness of DRESS syndrome
among physicians and to emphasize the importance of
early diagnosis and treatment. We also aim to highlight the
value of a multidisciplinary approach and proper follow up,
which is crucial for the long-term prognosis of DRESS
syndrome patients.
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